Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Instagram Outage Disrupts Thousands of U.S. Users 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
MONTPELLIER, France, April 08, 2016 -- MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing surgical robots, has today announced its revenue for the fiscal third quarter of 2016 (3 months ended March 31, 2016).
| In thousands of Euros | 2014/2015 | 2015/2016 | |
| H1 Revenue (July 1 to September 30) | 1 688 | 3 960 | |
| Q3 Revenue (January 1 to March 31) | 1 720 | 3 105 | |
| 9-month Revenue (July 1 to March 31) | 3 408 | 7 065 | |
Steady growth momentum throughout Q3
During the 3rd quarter of the 2015/16 fiscal period, Medtech continued to expand with steady progress in revenue of €3.1 million, up 81% compared with the same period in the prior year. With the sale of 10 new ROSA™ systems during the quarter (7 in the United States, 2 in China and 1 in France), Medtech has pursued its strategy to increase market share. Furthermore, this quarter Medtech recorded the first sale of its ROSA™ Spine robot in the United States, following FDA clearance in January 2016.
At the end of the first 9 months of the 2015/16 fiscal period, Medtech reported revenue of €7.1 million, up 107% compared to the same period in the prior year.
Third quarter revenue from the sale of service contracts was €310,000 compared with €228,000 for the same period in the prior year.
At the end of March 2016, the fleet of ROSA™ systems delivered worldwide was 69, including 21 delivered over the first 9 months of the 2015/16 fiscal period, demonstrating the Company’s steady execution of its commercial expansion strategy.
Cash available as of March 31, 2016 was €20.2 million, compared with €23.8 million as of December 31, 2015 and €12.6 million as of March 31, 2015.
Bertin Nahum, CEO and Founder of Medtech said, “Our fiscal third quarter performance clearly illustrates the growth momentum to which we are committed and confirms our strategy to conquer new markets, especially on an international scale.”
About MEDTECH
Founded in 2002 by Bertin NAHUM and based in Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.
In 2007, MEDTECH developed ROSA™, an innovative technological device devoted to brain surgery procedures. ROSA™ has been approved in Europe, the United States and Canada.
In 2013 MEDTECH received the “European Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine.
In October 2014, MEDTECH won the “Révélation” prize in the Mediterranean Deloitte Technology Fast 50 Awards.
In 2015 MEDTECH received the “2016 Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In November 2015, MEDTECH was honored by Deloitte In Extenso for its excellent performance in the Technology Fast 50 Mediterranean Awards, in the “listed company” category.
In January 2016, MEDTECH obtained the FDA clearance for its new product, ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine.
CONTACT MEDTECH Christophe Sibillin Chief Financial Officer Tel : +33 (0)4 67 10 77 40 INVESTORS Corinne Puissant Tel : +33 (0)1 53 67 36 77 [email protected] PRESS Alexandra Prisa (EU) Tel. : +33(0)1 53 67 36 90 [email protected] Joanna Zimmerman (US) Tel : +1 646-536-7006 [email protected]
